Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $161,115 | 64 | 73.2% |
| Consulting Fee | $23,400 | 6 | 10.6% |
| Travel and Lodging | $22,322 | 59 | 10.1% |
| Food and Beverage | $12,989 | 349 | 5.9% |
| Education | $275.81 | 13 | 0.1% |
| Unspecified | $0 | 4 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $212,577 | 367 | $0 (2024) |
| AbbVie Inc. | $3,465 | 26 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,376 | 56 | $0 (2024) |
| Allergan Inc. | $189.87 | 4 | $0 (2019) |
| FUJIFILM Healthcare Americas Corporation | $167.41 | 2 | $0 (2021) |
| Phadia US Inc. | $156.72 | 1 | $0 (2017) |
| Medtronic, Inc. | $147.54 | 1 | $0 (2022) |
| INTRA-SANA LABORATORIES | $125.04 | 1 | $0 (2021) |
| INTERCEPT PHARMACEUTICALS, INC. | $119.37 | 7 | $0 (2023) |
| BOSTON SCIENTIFIC CORPORATION | $117.06 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,148 | 25 | Gilead Sciences, Inc. ($10,989) |
| 2023 | $13,473 | 34 | Gilead Sciences, Inc. ($13,277) |
| 2022 | $37,548 | 59 | Gilead Sciences, Inc. ($37,198) |
| 2021 | $15,982 | 58 | Gilead Sciences, Inc. ($15,465) |
| 2020 | $6,873 | 24 | Gilead Sciences, Inc. ($6,772) |
| 2019 | $44,537 | 108 | Gilead Sciences, Inc. ($39,685) |
| 2018 | $35,271 | 74 | Gilead Sciences, Inc. ($34,374) |
| 2017 | $55,271 | 113 | Gilead Sciences Inc ($54,815) |
All Payment Transactions
495 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.28 | General |
| 10/26/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $148.79 | General |
| Category: INFLAM | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Gastroenterology | ||||||
| 09/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.35 | General |
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: Gastroenterology | ||||||
| 09/04/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $109.01 | General |
| Category: INFLAM | ||||||
| 08/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.41 | General |
| 07/26/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| Category: HBV | ||||||
| 07/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.01 | General |
| 06/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Gastroenterology | ||||||
| 05/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $65.15 | General |
| 04/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Gastroenterology | ||||||
| 04/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.11 | General |
| 04/10/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| Category: HBV | ||||||
| 03/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.64 | General |
| 03/24/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $571.36 | General |
| Category: HBV | ||||||
| 03/24/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $94.00 | General |
| Category: HBV | ||||||
| 03/23/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HBV | ||||||
| 03/23/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: HBV | ||||||
| 03/23/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: HBV | ||||||
| 03/01/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| 02/23/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $469.21 | General |
| Category: HBV | ||||||
| 02/21/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Gastroenterology | ||||||
| 02/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $116.15 | General |
| 2024 | GastroGPO, LLC | — | — | — | $0.00 | Ownership |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 415 | 469 | $159,850 | $38,048 |
| 2022 | 7 | 408 | 482 | $178,792 | $36,754 |
| 2021 | 6 | 291 | 386 | $108,852 | $28,607 |
| 2020 | 6 | 388 | 519 | $155,837 | $36,023 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 75 | 75 | $63,525 | $10,175 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 129 | 167 | $24,716 | $9,603 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 84 | 99 | $21,483 | $8,668 | 40.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $10,624 | $3,845 | 36.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 41 | 42 | $28,560 | $3,114 | 10.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 41 | 41 | $8,979 | $2,147 | 23.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 13 | 13 | $1,963 | $496.08 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 135 | 201 | $29,748 | $10,961 | 36.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 74 | 74 | $62,678 | $8,154 | 13.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 59 | $12,803 | $4,995 | 39.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 19 | 19 | $20,273 | $3,476 | 17.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 49 | 49 | $32,380 | $3,427 | 10.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 30 | $9,960 | $2,934 | 29.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 50 | 50 | $10,950 | $2,807 | 25.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 137 | 229 | $33,892 | $14,005 | 41.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 46 | 47 | $39,264 | $5,760 | 14.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 57 | 57 | $12,483 | $4,036 | 32.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 26 | 28 | $16,408 | $2,152 | 13.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $3,984 | $1,439 | 36.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 13 | $2,821 | $1,216 | 43.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 178 | 307 | $45,436 | $15,437 | 34.0% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 54 | 55 | $46,585 | $6,777 | 14.5% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 82 | 82 | $17,958 | $5,564 | 31.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 41 | 42 | $24,612 | $3,402 | 13.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 14 | 14 | $14,938 | $2,871 | 19.2% |
About Dr. Charles Phan, M.D
Dr. Charles Phan, M.D is a Gastroenterology healthcare provider based in Sugar Land, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457303737.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Phan, M.D has received a total of $220,102 in payments from pharmaceutical and medical device companies, with $11,148 received in 2024. These payments were reported across 495 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($161,115).
As a Medicare-enrolled provider, Phan has provided services to 1,502 Medicare beneficiaries, totaling 1,856 services with total Medicare billing of $139,432. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Sugar Land, TX
- Active Since 05/16/2006
- Last Updated 08/05/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1457303737
Products in Payments
- Vemlidy (Drug) $134,259
- Epclusa (Drug) $21,766
- Vosevi (Drug) $4,278
- Mavyret (Drug) $3,011
- XIFAXAN (Drug) $2,226
- Creon (Drug) $361.09
- Livdelzi (Drug) $257.80
- LINZESS (Drug) $189.87
- uTASWako AFP-L3 (Device) $167.41
- TRULANCE (Drug) $164.30
- ImmunoCAP (Device) $156.72
- INTERSTIM (Device) $147.54
- RELTONE 200 MG (Drug) $125.04
- Truvada (Drug) $125.00
- OCALIVA (Drug) $119.37
- GENERAL BRADY (Device) $117.06
- Linzess (Drug) $97.66
- ZONTIVITY (Drug) $68.72
- Viekira (Drug) $66.03
- GATTEX (Drug) $64.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Sugar Land
Robert Davis, M.d, M.D
Gastroenterology — Payments: $10,999
Dr. Leka Gajula, Md, MD
Gastroenterology — Payments: $10,235
Dr. Pragnesh Patel, Md, MD
Gastroenterology — Payments: $7,476
J Trabanino, M.d, M.D
Gastroenterology — Payments: $7,085
Dr. Stanley Stein, M.d, M.D
Gastroenterology — Payments: $6,633
Dr. Ephraim Nsien, Md, MD
Gastroenterology — Payments: $4,662